×
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
NASDAQ:ARAV

Aravive (ARAV) Stock Forecast, Price & News

$1.22
+0.09 (+7.96%)
(As of 05/27/2022 04:00 PM ET)
Add
Compare
Today's Range
$1.14
$1.26
50-Day Range
$1.06
$2.01
52-Week Range
$1.02
$6.94
Volume
125,977 shs
Average Volume
66,304 shs
Market Capitalization
$35.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.57
30 days | 90 days | 365 days | Advanced Chart
Receive ARAV News and Ratings via Email

Sign-up to receive the latest news and ratings for Aravive and its competitors with MarketBeat's FREE daily newsletter.

Aravive logo

About Aravive

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Headlines

Aravive (NASDAQ:ARAV) PT Lowered to $6.00 at Piper Sandler
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARAV
Fax
N/A
Employees
17
Year Founded
N/A

Sales & Book Value

Annual Sales
$7.44 million
Book Value
$1.36 per share

Profitability

Net Income
$-39.15 million
Net Margins
-533.99%
Pretax Margin
-533.99%

Debt

Price-To-Earnings

Miscellaneous

Free Float
14,386,000
Market Cap
$35.17 million
Optionable
Optionable

Company Calendar

Last Earnings
5/12/2022
Today
5/27/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.18 out of 5 stars

Medical Sector

396th out of 1,424 stocks

Pharmaceutical Preparations Industry

160th out of 681 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -













Aravive (NASDAQ:ARAV) Frequently Asked Questions

Is Aravive a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aravive stock.
View analyst ratings for Aravive
or view top-rated stocks.

When is Aravive's next earnings date?

Aravive is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Aravive
.

How were Aravive's earnings last quarter?

Aravive, Inc. (NASDAQ:ARAV) posted its earnings results on Thursday, May, 12th. The company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by $0.08. Aravive had a negative trailing twelve-month return on equity of 88.49% and a negative net margin of 533.99%.
View Aravive's earnings history
.

What price target have analysts set for ARAV?

1 Wall Street analysts have issued 12 month target prices for Aravive's stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate Aravive's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 391.8% from the stock's current price.
View analysts' price targets for Aravive
or view top-rated stocks among Wall Street analysts.

Who are Aravive's key executives?
Aravive's management team includes the following people:
  • Dr. Fredric N. Eshelman Pharm.D., Exec. Chairman (Age 73, Pay $95k)
  • Dr. Gail F. McIntyre CH (ASCP), DABT, Ph.D., Pres, CEO & Director (Age 59, Pay $699.7k)
  • Mr. Vinay Shah MBA, Chief Financial Officer (Age 59, Pay $496.5k)
  • Dr. Jeffrey L. Cleland Ph.D., Co-Founder (Age 57)
  • Dr. Joshua Silverman Ph.D., Co-Founder
  • Dr. Leonard Scott Dove Ph.D., Chief Operating Officer (Age 49)
  • Mr. Marek Ciszewski J.D., VP of Investor Relations
  • Dr. Randy L. Anderson, Sr. VP of Data Sciences
  • Kenneth L. Guernsey, Sec.
What other stocks do shareholders of Aravive own?
What is Aravive's stock symbol?

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

Who are Aravive's major shareholders?

Aravive's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.17%), Renaissance Technologies LLC (1.32%), UBS Group AG (0.19%), Bradley & Co. Private Wealth Management LLC (0.09%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Aravive stock include Amato Giaccia, Gail Frances Mcintyre and Vinay Shah.
View institutional ownership trends for Aravive
.

Which major investors are selling Aravive stock?

ARAV stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc., and UBS Group AG.
View insider buying and selling activity for Aravive
or view top insider-selling stocks.

Which major investors are buying Aravive stock?

ARAV stock was purchased by a variety of institutional investors in the last quarter, including Bradley & Co. Private Wealth Management LLC. Company insiders that have bought Aravive stock in the last two years include Gail Frances Mcintyre, and Vinay Shah.
View insider buying and selling activity for Aravive
or or view top insider-buying stocks.

How do I buy shares of Aravive?

Shares of ARAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aravive's stock price today?

One share of ARAV stock can currently be purchased for approximately $1.22.

How much money does Aravive make?

Aravive has a market capitalization of $35.17 million and generates $7.44 million in revenue each year. The company earns $-39.15 million in net income (profit) each year or ($2.12) on an earnings per share basis.

How many employees does Aravive have?

Aravive employs 17 workers across the globe.

What is Aravive's official website?

The official website for Aravive is www.aravive.com.

How can I contact Aravive?

Aravive's mailing address is River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098. The company can be reached via phone at (936) 355-1910 or via email at [email protected].

This page was last updated on 5/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.